Skip to main content
. 2013 Feb;20(1):24–29. doi: 10.3747/co.20.1202

TABLE III.

Results of Cox proportional hazards analysis on overall survivala

Variable hr 95% ci p Value Impact on survival
Line of chemotherapy 1.39 1.05 to 1.84 0.021 ↑ Risk by 39% per line
Achievement of clinical benefita 0.14 0.06 to 0.33 0.001 ↓ Risk by 86%
a

Schedule of nab-paclitaxel was not a significant predictor of overall survival, nor was the interaction between nab-paclitaxel schedule and achievement of clinical benefit.